Esperion Therapeutics, Inc. (ESPR)

Market Cap	748.67M +76.7%
Revenue (ttm)	303.80M +2.8%
Net Income	-105.83M
EPS	-0.54
Shares Out	235.43M
PE Ratio	n/a
Forward PE	9.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,989,155
Open	3.400
Previous Close	3.420
Day's Range	3.160 - 3.495
52-Week Range	0.693 - 4.175
Beta	1.11
Analysts	Buy
Price Target	6.67 (+109.75%)
Earnings Date	Mar 3, 2026

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LD...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 26, 2013
• Employees: 304
• Stock Exchange: NASDAQ
• Ticker Symbol: ESPR
• Website: https://www.esperion.com

Financial Performance

In 2024, Esperion Therapeutics's revenue was $332.31 million, an increase of 185.66% compared to the previous year's $116.33 million. Losses were -$51.75 million, -75.27% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price target is $6.67, which is an increase of 109.75% from the latest price.

Price Target

$6.67

(109.75% upside)

Analyst Consensus: Buy